EUCTR2006-003142-42-DE
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo-controlled, Proof of Concept Study to evaluate Efficacy, Safety and Pharmacokinetics of two Different Doses of SC12267 (20mg, 35 mg) in Patients with Rheumatoid Arthritis
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Active Rheumatoid Arthritis
- 发起方
- 4SC AG
- 入组人数
- 120
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •6\.2Subject Inclusion Criteria
- •Subjects meeting all of the following inclusion criteria will be considered for admission to the trial:
- •1\.Regarding demographic data:
- •Age:From 18 years
- •Gender:Males and females
- •Race:Caucasian
- •BMI:19 \- 30 kg/m2
- •2\.Regarding RA:
- •Patients with early active RA of functional classes I, II or III according to the criteria of American Rheumatism Association for RA
- •DAS28(CRP) \= 4\.1
排除标准
- •6\.3Subject Exclusion Criteria
- •Subjects presenting any of the following exclusion criteria cannot be admitted to the trial:
- •1\.Regarding RA:
- •Patients with RA of functional classes IV according to the criteria of American Rheumatism Association for RA
- •2\.Regarding pre\-treatment of RA and concomitant medication:
- •History of treatment with one of the following drugs:
- •Leflunomide
- •Oral or injectable gold
- •Cyclophosphamide
- •Biologicals
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Evaluation of Dupilumab in Patients with Persistent AsthmaAsthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-004940-36-DESanofi-aventis Recherche & Développement1,858
进行中（未招募）
不适用
Evaluation of Dupilumab in Patients with Persistent AsthmaAsthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-004940-36-Outside-EU/EEASanofi-aventis Recherche & Développement1,638
进行中（未招募）
1 期
Efficacy and Safety of Sotagliflozin versus Placebo in Subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control while Taking Insulin Alone or with Other Oral Antidiabetic AgentsType 2 diabetes mellitusMedDRA version: 20.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2016-001804-43-BGSanofi-aventis Recherche & Développement571
进行中（未招募）
不适用
Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid TherapyEUCTR2013-002948-91-ATShionogi Inc.540
进行中（未招募）
1 期
GRAVITI - A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn's DiseaseModerately to Severely Active Crohn's DiseaseMedDRA version: 20.0Level: PTClassification code: 10011401Term: Crohn's disease Class: 100000004856Therapeutic area: Diseases [C] - Immune System Diseases [C20]CTIS2023-504737-41-00Janssen - Cilag International510